Dr. Burdick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12040 NE 128th St
Stop 11
Kirkland, WA 98034Phone+1 425-899-3123Fax+1 425-899-3114
Education & Training
Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Neurology, 2007 - 2010- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2006 - 2007
Johns Hopkins University School of MedicineClass of 2006
Certifications & Licensure
WA State Medical License 2010 - 2026- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Cerner Modular EHR, Cerner Corporation, 2013
Clinical Trials
- A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) Start of enrollment: 2014 Mar 01
- Flexible-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2020 Jan 06
- Open-label Trial in Parkinson's Disease (PD) Start of enrollment: 2021 Feb 24
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- 108 citationsDiscovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.Anthony A. Estrada, Xingrong Liu, Charles Baker-Glenn, Alan Beresford, Daniel J. Burdick
Journal of Medicinal Chemistry. 2012-10-15 - 61 citationsDiscovery of Selective LRRK2 Inhibitors Guided by Computational Analysis and Molecular ModelingHuifen Chen, Bryan K. Chan, Jason Drummond, Anthony A. Estrada, Janet Gunzner-Toste
Journal of Medicinal Chemistry. 2012-06-01 - 62 citationsPeople with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.Daniel J. Burdick, Brenna Cholerton, G. S. Watson, Andrew Siderowf, John Q. Trojanowski
Movement Disorders. 2014-09-01
Press Mentions
1st Patient Treated in SHAPE Trial of ATH-1017 for Parkinson’s DementiaJanuary 28th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
